Top-Rated StocksTop-RatedNASDAQ:RPRX Royalty Pharma (RPRX) Stock Price, News & Analysis $69.31 +0.34 (+0.49%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$68.64 -0.67 (-0.97%) As of 11/13/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Royalty Pharma Stock (NASDAQ:RPRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Royalty Pharma alerts:Sign Up Key Stats Today's Range$68.14▼$69.4350-Day Range$56.21▼$70.0152-Week Range$37.31▼$70.37Volume2.95 million shsAverage Volume3.55 million shsMarket Capitalization$39.85 billionP/E Ratio57.76Dividend Yield1.36%Price Target$63.29Consensus RatingBuy Company Overview Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company’s portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself. Founded in 1996 by Pablo Legorreta, the company became publicly listed in 2020. Legorreta serves as its chairman and chief executive officer. Royalty Pharma works with biopharmaceutical companies and research institutions internationally, with a business focused on the global life sciences sector.AI Generated. May Contain Errors. Read More Royalty Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreRPRX MarketRank™: 3.61081932773 of 5 starsRoyalty Pharma scored higher than 72% of companies evaluated by MarketBeat, and ranked 190th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingBuy Consensus RatingRoyalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 1 strong buy rating, 8 buy ratings, no hold ratings, and no sell ratings.Downside RiskRoyalty Pharma has a consensus price target of $63.29, representing about 8.7% downside from its current price of $69.31.Amount of Analyst CoverageRoyalty Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Royalty Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth7.65% Earnings GrowthEarnings for Royalty Pharma are expected to grow by 7.65% in the coming year, from $5.36 to $5.77 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 57.76, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 57.76, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 1.37. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.80% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 3.97, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Royalty Pharma has recently increased by 1.81%, indicating that investor sentiment is decreasing. Dividend2.5 / 5Dividend StrengthModerate Dividend YieldRoyalty Pharma pays a meaningful dividend of 1.36%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma has been increasing its dividend for 5 years.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 78.33%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 16.29% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.Read more about Royalty Pharma's dividend. News and Social Media3.8 / 5News Sentiment1.12 News SentimentRoyalty Pharma has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Royalty Pharma this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for RPRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows8 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,324,407.00 in company stock.Percentage Held by Insiders18.84% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Royalty Pharma's insider trading history. Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RPRX Stock News HeadlinesRoyalty Pharma to present at the UBS Global Biopharma ConferenceNovember 12 at 4:15 PM | globenewswire.comRoyalty Pharma: Stronger Royalty Growth Supports Further UpsideNovember 12 at 9:14 AM | seekingalpha.comManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.November 14 at 1:00 AM | Monument Traders Alliance (Ad)Royalty Pharma PLC (NASDAQ:RPRX) Stock Has Consensus Target Price of $63.29 According to BrokeragesNovember 12 at 3:47 AM | americanbankingnews.com3 Biotech Stocks That Actually Pay Dividends and Keep Raising ThemNovember 10, 2026 | 247wallst.comWhy Royalty Pharma Investors Could Be the Quiet Winners From Revolution Medicines' Groundbreaking Pancreatic Cancer DrugNovember 8, 2026 | fool.comHow Investors Are Reacting To Royalty Pharma (RPRX) Earnings BeatNovember 7, 2026 | finance.yahoo.comRoyalty Pharma (RPRX) Stock Looks Fully Valued After A 168% RunNovember 6, 2026 | finance.yahoo.comSee More Headlines RPRX Stock Analysis - Frequently Asked Questions How have RPRX shares performed this year? Royalty Pharma's stock was trading at $38.64 at the start of the year. Since then, RPRX stock has increased by 79.4% and is now trading at $69.31. How were Royalty Pharma's earnings last quarter? Royalty Pharma PLC (NASDAQ:RPRX) released its earnings results on Wednesday, August, 5th. The biopharmaceutical company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.27 by $0.05. The biopharmaceutical company earned $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. Royalty Pharma had a net margin of 25.68% and a trailing twelve-month return on equity of 30.04%. Read the conference call transcript. When did Royalty Pharma IPO? Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering (IPO) on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. Who are Royalty Pharma's major shareholders? Top institutional shareholders of Royalty Pharma include State Street Corp (2.25%), New South Capital Management Inc. (0.25%), Russell Investments Group Ltd. (0.25%) and Robeco Institutional Asset Management B.V. (0.20%). Insiders that own company stock include Avara Management Ltd, Christopher Hite, Gregory Norden, Rory B Riggs, Terrance P Coyne, Marshall Urist and George W Lloyd. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Royalty Pharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Palantir Technologies (PLTR), Micron Technology (MU), Pfizer (PFE) and Salesforce (CRM). Company Calendar Last Earnings8/05/2026Record date for 9/10 Dividend8/14/2026Ex-Dividend for 9/10 Dividend8/14/2026Dividend Payable9/10/2026Record date for 12/10 Dividend11/13/2026Ex-Dividend for 12/10 Dividend11/13/2026Today11/14/2026UBS Global Biopharma Conference 202611/17/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Dividend Payable12/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 RPRX's financial health is in the Green zone, according to TradeSmith. RPRX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RPRX CIK1802768 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees100Year Founded1996Price Target and Rating Average Price Target for Royalty Pharma$63.29 High Price Target$78.00 Low Price Target$45.00 Potential Upside/Downside-8.7%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)$1.20 Trailing P/E Ratio57.76 Forward P/E Ratio12.01 P/E Growth1.37Net Income$770.95 million Net Margins25.68% Pretax Margin44.83% Return on Equity30.04% Return on Assets14.97% Debt Debt-to-Equity Ratio0.77 Current Ratio1.29 Quick Ratio1.29 Sales & Book Value Annual Sales$2.38 billion Price / Sales16.76 Cash Flow$4.80 per share Price / Cash Flow14.44 Book Value$17.03 per share Price / Book4.07Miscellaneous Outstanding Shares575,000,000Free Float466,671,000Market Cap$39.85 billion OptionableOptionable Beta0.37 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:RPRX) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
